In chronic myeloid leukemia (CML), ETS1 is associated with the BCR-ABL signaling pathway, regulates granulocyte differentiation, and is downregulated during tyrosine kinase inhibitor (TKI) treatment (179). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.